Changeflow GovPing Healthcare & Life Sciences CD3 Binding Antibodies Patent Application Inven...
Routine Notice Added Final

CD3 Binding Antibodies Patent Application Inventors Listed

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260085115A1, related to CD3 binding antibodies. The application, filed on June 2, 2025, lists inventors Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, and Duy Pham.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The United States Patent and Trademark Office (USPTO) has published patent application US20260085115A1, titled 'CD3 BINDING ANTIBODIES'. The application, filed on June 2, 2025, lists five inventors and describes human CD3 antigen-binding polypeptides and their preparation and use in treating and diagnosing diseases, as well as bispecific antibody molecules for activating immune effector cells.

This publication is a notice of a new patent application and does not impose new regulatory obligations. Companies involved in the development or research of CD3 binding antibodies or related bispecific antibody technologies should be aware of this intellectual property filing. No immediate compliance actions are required, but it may inform R&D strategies and competitive landscape analysis.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CD3 BINDING ANTIBODIES

Application US20260085115A1 Kind: A1 Mar 26, 2026

Inventors

Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham

Abstract

The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

CPC Classifications

C07K 16/2809 C07K 16/2878 C07K 2317/31 C07K 2317/52 C07K 2317/565 C07K 2317/567 C07K 2317/622 C07K 2317/71 C07K 2317/732 C07K 2317/734 C07K 2317/92

Filing Date

2025-06-02

Application No.

19225896

View original document →

Named provisions

Inventors Abstract

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
June 2nd, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085115A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Biotechnology Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!